BLOOD, WHOLE
Malignant Testicular Neoplasm
Mayo Clinicother_biologicalActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Malignant Testicular Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinorelbine National Cancer Institute (NCI) | Phase 1 | CC |
Cediranib National Cancer Institute (NCI) | Phase 1 | CC |
Carboplatin National Cancer Institute (NCI) | Phase 1 | CC |
Veliparib National Cancer Institute (NCI) | Phase 1 | CC |
FAPi-46 Jonsson Comprehensive Cancer Center | Phase 1 | CC |
FLUDEOXYGLUCOSE Jonsson Comprehensive Cancer Center | Phase 1 | CC |
Same molecule, other indications
BLOOD, WHOLE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →